The multiple of 1.65 x EBITDA is fantastic and the scale benefits would also be upside given they're not modelled in the announcement.
Funding through convertible debt rather than share issue is also an ok idea.
Considering adding to the holding - leverage to a global brand with recurring revenue streams in a modernising and tech savvy emerging market is no bad thing - especially when it's already profitable and easy to understand
- Forums
- ASX - By Stock
- SRY
- Ann: Acquisition of Additional Businesses
Ann: Acquisition of Additional Businesses, page-8
Featured News
Add SRY (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.505M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
SRY (ASX) Chart |
Day chart unavailable
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
Previous Video
Next Video
SPONSORED BY The Market Online